Search Eyecare Jobs now

BREAKING News Actavis to Acquire Allergan Transaction Valued at 66 Billion

Transaction Valued at $66 Billion or $219 per Share in Cash and Actavis Shares -
- Fastest Growing, Most Dynamic Pharmaceutical Company in Global Healthcare -
- Leading Blockbuster Franchises in Ophthalmology, Neurosciences/CNS, Medical Aesthetics/Dermatology/Plastic Surgery, Women’s Health, Gastroenterology and Urology -
- Positioned for Long-Term Double-Digit Organic Revenue and Earnings Growth -
- Double-Digit Accretion to Non-GAAP EPS within First 12 Months -
- Expands International Presence with Greater Market and Product Reach -
- Projected Synergies of at Least $1.8 Billion while Maintaining R&D Commitment of Approximately $1.7 Billion -

To view complete article click here to go to Optical Prism: